Respiri Limited (ASX: RSH)
Respiri Limited (ASX: RSH) is a technologically focused medical device company offering products to the respiratory health segment. www.respiri.co
Respiri engages Entech Electronics to manufacture wheezo at ‘significantly’ improved cost
Health technology company Respiri (ASX: RSH) has engaged Entech Electronics to manufacture its “ground breaking” wheezo device offshore in China...
Respiri unveils promising wheezo clinical study results
Preliminary results of a clinical study involving the wheezo asthma management platform made by eHealth technology developer Respiri (ASX: RSH) ...
Respiri teams up with Carlton Football Club to promote wheezo device
A day after publishing its full year accounts, eHealth company Respiri (ASX: RSH) has tentatively set foot in Australian rules football courtesy...
Respiri signs referral agreement with APA to proliferate wheezo in Australia
eHealth company Respiri (ASX: RSH) has taken another step towards growing sales of its wheezo device ahead of its October launch, after signing ...
Respiri partners with Australian Patients Association for wheezo study
eHealth Software-as-a-Service (Saas) company Respiri (ASX: RSH) has updated the market with news it has entered into a partnership with the Aust...
eHealth SaaS provider Respiri targets $6-8m revenue for 2021
eHealth technology developer and maker of the wheezo device, Respiri (ASX: RSH) has published interim revenue guidance for 2021 with total reven...
Respiri accelerates wheezo commercialisation by teaming up with BNPL company Zip
Wheezo developer Respiri’s (ASX: RSH) commercialisation path will accelerate even further after the company collared a deal with renowned buy no...
Respiri secures global sales and distribution agreement for wheezo asthma monitoring device
Healthcare technology developer Respiri (ASX: RSH) has signed an exclusive agreement with global respiratory pharmaceutical firm Cipla for the s...
Respiri partners with UK data research centre in preparation for Wheezo’s EU launch
eHealth software company Respiri (ASX: RSH) has unveiled a new partnership agreement with the University of Edinburgh to feed data from its prop...
Respiri grows wheezo market potential through agreement with the Pharmacy Guild of Australia
Respiri (ASX: RSH) has collared a two-year definitive service agreement with the Pharmacy Guild of Australia to develop an online pharmacist cou...
Shareholders back Respiri in heavily oversubscribed share purchase plan
Respiri (ASX: RSH) has topped up its cash reserves with $3.14 million after receiving “significant oversubscriptions” in a recent share purchase...
Respiri strikes telehealth deal with Aussie start-up to improve respiratory care for asthma patients
Respiratory health management company Respiri (ASX: RSH) has entered into commercial discussions with Australian start-up Practice Innovators In...
Respiri expands wheezo into telehealth market with Phenix partnership
Respiri (ASX: RSH) has expanded the market for its wheezo technology after announcing a partnership with Phenix Health.
The parties have inke...
Respiri experiences requests for wheezo devices to monitor COVID-19 patients in China
Respiratory focused SaaS company Respiri (ASX: RSH) has experienced inbound demand for its wheezo technology from three Chinese hospitals ...
Respiri’s Wheezo product approved for sale following CE Mark and TGA registration
Healthcare technology developer Respiri (ASX: RSH) has revealed that the company has received the highly coveted CE Mark and TGA approval to lis...
Appointment of professor Bruce Thompson provides Respiri clinical credibility
Bruce Thompson has been appointed as chair of Respiri’s (ASX: RSH) Australian medical and scientific Advisory board and product portfolio develo...
Respiri appoints SRX Global to manufacture wheeze and asthma sensor
Respiri (ASX: RSH) has ticked off another key milestone – a manufacturing agreement with SRX Global, to produce its next generation breath and a...
Respiri’s wheeze monitoring device to improve asthma management
Healthcare technology developer Respiri (ASX: RSH) is in the final stages of commercialising its asthma monitoring product called AirSonea.
I...